BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of marker genes starting with is 216
| GENE | HGNC_ID | CANCER_TYPE | HISTOLOGICAL_TYPE | CSC_ENRICHMENT | METHOD | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|
| ALDH1A1 | 402 | Breast Cancer | NA | NA | Western Blotting and IF staining followed by qRT-PCR | 0.96 | 0.684 | 30622340 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | qPCR followed by IHC staining | 0.96 | 0.684 | 29660692 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | ALDEFLUOR assay followed by SFA and qRT-PCR | 0.96 | 0.684 | 31728117 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 35083162 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 34644211 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 27994520 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 28766688 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 29306324 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 29336465 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 29416796 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 29843115 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 29845398 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 30364293 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | IHC staining | 0.96 | 0.684 | 31516750 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | FACs for CSC marker followed by qRT-PCR | 0.96 | 0.684 | 33799422 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | SFA followed by qRT-PCR | 0.96 | 0.684 | 28746471 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | SFA followed by qRT-PCR | 0.96 | 0.684 | 30587593 |
| ALDH1A1 | 402 | Breast Cancer | Ductal Carcinoma | Tamoxifen | SFA followed by qRT-PCR | 0.96 | 0.684 | 31693936 |
| ALDH1A1 | 402 | Breast Cancer | Ductal Carcinoma | Tamoxifen+Fulvestrant | SFA followed by qRT-PCR | 0.96 | 0.684 | 31693936 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | ALDEFLUOR assay | 0.96 | 0.684 | 34476645 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | ALDEFLUOR assay | 0.96 | 0.684 | 34778599 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | ALDEFLUOR assay | 0.96 | 0.684 | 33471244 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | ALDEFLUOR assay | 0.96 | 0.684 | 28588211 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | ALDEFLUOR assay followed by CFA | 0.96 | 0.684 | 34377198 |
| ALDH1A1 | 402 | Breast Cancer | NA | Doxorubicin | ALDEFLUOR assay followed by SFA | 0.96 | 0.684 | 33221681 |
| ALDH1A1 | 402 | Breast Cancer | NA | Carboplatin | ALDEFLUOR assay followed by SFA | 0.96 | 0.684 | 33221681 |
| ALDH1A1 | 402 | Breast Cancer | NA | Paclitaxel | ALDEFLUOR assay followed by SFA | 0.96 | 0.684 | 33221681 |
| ALDH1A1 | 402 | Breast Cancer | Ductal Carcinoma | NA | ALDEFLUOR assay followed by SFA | 0.96 | 0.684 | 30050081 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | FACs | 0.96 | 0.684 | 34073849 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | FACs | 0.96 | 0.684 | 34572409 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | SFA followed by ALDEFLUOR assay | 0.96 | 0.684 | 35053617 |
| ALDH1A1 | 402 | Breast Cancer | NA | Chemotherapy | SFA followed by ALDEFLUOR assay | 0.96 | 0.684 | 28835684 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | SFA followed by ALDEFLUOR assay | 0.96 | 0.684 | 28935760 |
| ALDH1A1 | 402 | Breast Cancer | NA | NA | SFA followed by FACs | 0.96 | 0.684 | 30359767 |
| SOX9 | 11204 | Breast Cancer | NA | NA | Western Blotting and IF staining followed by qRT-PCR | 0.96 | 0.0244 | 30622340 |
| SOX9 | 11204 | Breast Cancer | NA | Tamoxifen | SFA followed by qRT-PCR | 0.96 | 0.0244 | 30622340 |
| BGN | 1044 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR and Western Blotting | 0.76 | 0.0032 | 35053617 |
| DDX27 | 15837 | Breast Cancer | NA | NA | Western Blotting followed by IHC staining | 0.68 | 0.0011 | 34362383 |
| NANOG | 20857 | Breast Cancer | NA | NA | qPCR followed by IHC staining | 0.68 | 0.5461 | 29660692 |
| NANOG | 20857 | Breast Cancer | NA | Chemotherapy | SFA followed by Western Blotting | 0.68 | 0.5461 | 28835684 |
| NANOG | 20857 | Breast Cancer | NA | NA | SFA followed by qRT-PCR | 0.68 | 0.5461 | 30587593 |
| NANOG | 20857 | Breast Cancer | Ductal Carcinoma | Tamoxifen | SFA followed by qRT-PCR | 0.68 | 0.5461 | 31693936 |
| NANOG | 20857 | Breast Cancer | Ductal Carcinoma | Tamoxifen+Fulvestrant | SFA followed by qRT-PCR | 0.68 | 0.5461 | 31693936 |
| NANOG | 20857 | Breast Cancer | NA | NA | SFA followed by FACs | 0.68 | 0.5461 | 30359767 |
| NANOG | 20857 | Breast Cancer | NA | NA | SFA followed by Western Blotting and ICC staining | 0.68 | 0.5461 | 33340428 |
| B4GALNT1 | 4117 | Breast Cancer | NA | NA | qRT-PCR followed by ELISA | 0.64 | 0.0042 | 35321364 |
| B4GALNT1 | 4117 | Breast Cancer | NA | NA | IHC staining | 0.64 | 0.0042 | 33722905 |
| CD44 | 1681 | Breast Cancer | NA | NA | qPCR followed by IHC staining | 0.6 | 1 | 29660692 |
| CD44 | 1681 | Breast Cancer | Ductal Carcinoma | NA | qRT-PCR and FACs followed by SFA | 0.6 | 1 | 30050081 |
| CD44 | 1681 | Breast Cancer | NA | Doxorubicin | FACs followed by ALDEFLUOR assay | 0.6 | 1 | 33221681 |
| CD44 | 1681 | Breast Cancer | NA | Carboplatin | FACs followed by ALDEFLUOR assay | 0.6 | 1 | 33221681 |
| CD44 | 1681 | Breast Cancer | NA | Paclitaxel | FACs followed by ALDEFLUOR assay | 0.6 | 1 | 33221681 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 35083162 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 33274565 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 33731668 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 19385591 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 27994520 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 28766688 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 28977854 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 29306324 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 29416796 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 29434947 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 29843115 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 29845398 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 30364293 |
| CD44 | 1681 | Breast Cancer | NA | NA | IHC staining | 0.6 | 1 | 31516750 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs for CSC marker followed by qRT-PCR | 0.6 | 1 | 33799422 |
| CD44 | 1681 | Breast Cancer | NA | NA | SFA followed by qRT-PCR | 0.6 | 1 | 31728117 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs | 0.6 | 1 | 34476645 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs | 0.6 | 1 | 34778599 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs | 0.6 | 1 | 34073849 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs | 0.6 | 1 | 34572409 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs | 0.6 | 1 | 33471244 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs | 0.6 | 1 | 18685093 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs | 0.6 | 1 | 31555258 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs | 0.6 | 1 | 31555258 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs followed by SFA | 0.6 | 1 | 34195201 |
| CD44 | 1681 | Breast Cancer | NA | NA | FACs followed by SFA | 0.6 | 1 | 30587593 |
| CD44 | 1681 | Breast Cancer | NA | NA | MACs | 0.6 | 1 | 29344258 |
| CD44 | 1681 | Breast Cancer | NA | NA | SFA followed by FACs | 0.6 | 1 | 33340428 |
| CD44 | 1681 | Breast Cancer | NA | NA | SFA followed by FACs | 0.6 | 1 | 18083101 |
| CD44 | 1681 | Breast Cancer | NA | NA | SFA followed by FACs | 0.6 | 1 | 28746471 |
| CD44 | 1681 | Breast Cancer | NA | Chemotherapy | SFA followed by FACs | 0.6 | 1 | 28835684 |
| CD44 | 1681 | Breast Cancer | NA | NA | SFA followed by FACs | 0.6 | 1 | 29925435 |
| CD44 | 1681 | Breast Cancer | NA | NA | SFA followed by FACs | 0.6 | 1 | 30359767 |
| POU5F1 | 9221 | Breast Cancer | NA | NA | qPCR followed by IHC staining | 0.6 | 0.6448 | 29660692 |
| POU5F1 | 9221 | Breast Cancer | NA | Chemotherapy | SFA followed by Western Blotting | 0.6 | 0.6448 | 28835684 |
| POU5F1 | 9221 | Breast Cancer | NA | NA | Western Blotting | 0.6 | 0.6448 | 29185119 |
| POU5F1 | 9221 | Breast Cancer | Ductal Carcinoma | Tamoxifen | SFA followed by qRT-PCR | 0.6 | 0.6448 | 31693936 |
| POU5F1 | 9221 | Breast Cancer | Ductal Carcinoma | Tamoxifen+Fulvestrant | SFA followed by qRT-PCR | 0.6 | 0.6448 | 31693936 |
| POU5F1 | 9221 | Breast Cancer | NA | NA | SFA followed by qRT-PCR | 0.6 | 0.6448 | 31728117 |
| POU5F1 | 9221 | Breast Cancer | NA | NA | SFA followed by FACs | 0.6 | 0.6448 | 30359767 |
| POU5F1 | 9221 | Breast Cancer | NA | NA | SFA followed by Western Blotting | 0.6 | 0.6448 | 33340428 |
| POU5F1 | 9221 | Breast Cancer | NA | NA | IF staining | 0.6 | 0.6448 | 35402219 |
| POU5F1 | 9221 | Breast Cancer | NA | NA | IHC staining | 0.6 | 0.6448 | 35506041 |
| PROM1 | 9454 | Breast Cancer | NA | NA | qPCR followed by IHC staining | 0.6 | 0.7582 | 29660692 |
| PROM1 | 9454 | Breast Cancer | Adenocarcinoma | NA | IF staining | 0.6 | 0.7582 | 31791269 |
| PROM1 | 9454 | Breast Cancer | NA | NA | IHC staining | 0.6 | 0.7582 | 27994520 |
| PROM1 | 9454 | Breast Cancer | NA | NA | IHC staining | 0.6 | 0.7582 | 30542507 |
| PROM1 | 9454 | Breast Cancer | NA | NA | IHC staining | 0.6 | 0.7582 | 31516750 |
| PROM1 | 9454 | Breast Cancer | NA | NA | FACs followed by SFA | 0.6 | 0.7582 | 34195201 |
| CXCL1 | 4602 | Breast Cancer | NA | NA | FACs and IHC staining followed by SFA | 0.52 | 0.0064 | 34195201 |
| CD24 | 1645 | Breast Cancer | Ductal Carcinoma | NA | qRT-PCR and FACs followed by SFA | 0.48 | 0.456 | 30050081 |
| CD24 | 1645 | Breast Cancer | NA | NA | IHC staining | 0.48 | 0.456 | 35083162 |
| CD24 | 1645 | Breast Cancer | NA | NA | IHC staining | 0.48 | 0.456 | 33274565 |
| CD24 | 1645 | Breast Cancer | NA | NA | IHC staining | 0.48 | 0.456 | 33731668 |
| CD24 | 1645 | Breast Cancer | NA | NA | IHC staining | 0.48 | 0.456 | 27994520 |
| CD24 | 1645 | Breast Cancer | NA | NA | IHC staining | 0.48 | 0.456 | 28766688 |
| CD24 | 1645 | Breast Cancer | NA | NA | IHC staining | 0.48 | 0.456 | 28977854 |
| CD24 | 1645 | Breast Cancer | NA | NA | IHC staining | 0.48 | 0.456 | 29416796 |
| CD24 | 1645 | Breast Cancer | NA | NA | IHC staining | 0.48 | 0.456 | 29434947 |
| CD24 | 1645 | Breast Cancer | NA | NA | IHC staining | 0.48 | 0.456 | 29843115 |
| CD24 | 1645 | Breast Cancer | NA | NA | IHC staining | 0.48 | 0.456 | 31516750 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs for CSC marker followed by qRT-PCR | 0.48 | 0.456 | 33799422 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs | 0.48 | 0.456 | 34476645 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs | 0.48 | 0.456 | 34778599 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs | 0.48 | 0.456 | 34073849 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs | 0.48 | 0.456 | 34572409 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs | 0.48 | 0.456 | 33471244 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs | 0.48 | 0.456 | 31555258 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs | 0.48 | 0.456 | 18685093 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs | 0.48 | 0.456 | 31555258 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs | 0.48 | 0.456 | 31555258 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs followed by SFA | 0.48 | 0.456 | 34195201 |
| CD24 | 1645 | Breast Cancer | NA | NA | FACs followed by SFA | 0.48 | 0.456 | 30587593 |
| CD24 | 1645 | Breast Cancer | NA | NA | MACs | 0.48 | 0.456 | 29344258 |
| CD24 | 1645 | Breast Cancer | NA | NA | SFA followed by FACs | 0.48 | 0.456 | 33340428 |
| CD24 | 1645 | Breast Cancer | NA | NA | SFA followed by FACs | 0.48 | 0.456 | 18083101 |
| CD24 | 1645 | Breast Cancer | NA | NA | SFA followed by FACs | 0.48 | 0.456 | 28746471 |
| CD24 | 1645 | Breast Cancer | NA | Chemotherapy | SFA followed by FACs | 0.48 | 0.456 | 28835684 |
| CD24 | 1645 | Breast Cancer | NA | NA | SFA followed by FACs | 0.48 | 0.456 | 29925435 |
| CD24 | 1645 | Breast Cancer | NA | NA | SFA followed by FACs | 0.48 | 0.456 | 30359767 |
| ITGA6 | 6142 | Breast Cancer | Ductal Carcinoma | NA | qRT-PCR and FACs followed by SFA | 0.48 | 0.0265 | 30050081 |
| ITGA6 | 6142 | Breast Cancer | NA | NA | FACs | 0.48 | 0.0265 | 31555258 |
| ITGA6 | 6142 | Breast Cancer | NA | NA | FACs | 0.48 | 0.0265 | 31555258 |
| ITGA6 | 6142 | Breast Cancer | NA | NA | FACs | 0.48 | 0.0265 | 34572409 |
| NPTX1 | 7952 | Breast Cancer | NA | NA | FACs and qRT-PCR followed by SFA | 0.48 | 0.0032 | 30587593 |
| ALDH1A3 | 409 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0201 | 35053617 |
| CCL11 | 10610 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0011 | 35053617 |
| CCL2 | 10618 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0074 | 35053617 |
| CCL5 | 10632 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0064 | 35053617 |
| CCL7 | 10634 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0011 | 35053617 |
| COL17A1 | 2194 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0064 | 35053617 |
| COL1A2 | 2198 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0021 | 35053617 |
| COL2A1 | 2200 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0021 | 35053617 |
| COL3A1 | 2201 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0021 | 35053617 |
| COL6A1 | 2211 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0021 | 35053617 |
| COL7A1 | 2214 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0032 | 35053617 |
| DCN | 2705 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0011 | 35053617 |
| KRT5 | 6442 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0064 | 35053617 |
| LAMA3 | 6483 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0053 | 35053617 |
| POSTN | 16953 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0042 | 35053617 |
| TP63 | 15979 | Breast Cancer | NA | NA | FACs for CSC marker and Transcriptomics followed by qRT-PCR | 0.4 | 0.0032 | 35053617 |
| ABCG2 | 74 | Breast Cancer | NA | Chemotherapy | SFA followed by Western Blotting | 0.36 | 0.1739 | 28835684 |
| ALDH1A1 | 402 | Triple Negative Breast Cancer | NA | NA | SFA followed by Western Blotting | 0.36 | 0.684 | 33924995 |
| DCLK1 | 2700 | Triple Negative Breast Cancer | NA | NA | SFA followed by Western Blotting | 0.36 | 0.0159 | 33924995 |
| HES1 | 5192 | Triple Negative Breast Cancer | NA | NA | SFA followed by Western Blotting | 0.36 | 0.0095 | 33924995 |
| HEY1 | 4880 | Triple Negative Breast Cancer | NA | NA | SFA followed by Western Blotting | 0.36 | 0.0021 | 33924995 |
| JAG1 | 6188 | Triple Negative Breast Cancer | NA | NA | SFA followed by Western Blotting | 0.36 | 0.0117 | 33924995 |
| KLF4 | 6348 | Breast Cancer | NA | NA | Western Blotting | 0.36 | 0.0891 | 29185119 |
| MYC | 7553 | Breast Cancer | NA | NA | Western Blotting | 0.36 | 0.1304 | 29185119 |
| MYC | 7553 | Breast Cancer | Ductal Carcinoma | Tamoxifen | SFA followed by qRT-PCR | 0.36 | 0.1304 | 31693936 |
| MYC | 7553 | Breast Cancer | Ductal Carcinoma | Tamoxifen+Fulvestrant | SFA followed by qRT-PCR | 0.36 | 0.1304 | 31693936 |
| MYC | 7553 | Breast Cancer | NA | NA | SFA followed by Western Blotting | 0.36 | 0.1304 | 33340428 |
| NOTCH1 | 7881 | Triple Negative Breast Cancer | NA | NA | SFA followed by Western Blotting | 0.36 | 0.0477 | 33924995 |
| PROM1 | 9454 | Triple Negative Breast Cancer | NA | NA | SFA followed by Western Blotting | 0.36 | 0.7582 | 33924995 |
| SOX2 | 11195 | Breast Cancer | NA | NA | SFA followed by Western Blotting | 0.36 | 0.5695 | 33340428 |
| SOX2 | 11195 | Breast Cancer | NA | Chemotherapy | SFA followed by Western Blotting | 0.36 | 0.5695 | 28835684 |
| SOX2 | 11195 | Breast Cancer | NA | NA | IF staining | 0.36 | 0.5695 | 35402219 |
| SOX2 | 11195 | Breast Cancer | NA | NA | SFA followed by qRT-PCR | 0.36 | 0.5695 | 28746471 |
| SOX2 | 11195 | Breast Cancer | NA | NA | SFA followed by FACs | 0.36 | 0.5695 | 30359767 |
| WNT1 | 12774 | Breast Cancer | NA | Chemotherapy | SFA followed by Western Blotting | 0.36 | 0.0074 | 28835684 |
| BMI1 | 1066 | Breast Cancer | NA | NA | IHC staining | 0.32 | 0.1135 | 18269588 |
| EPCAM | 11529 | Breast Cancer | Adenocarcinoma | NA | IF staining | 0.32 | 0.211 | 31791269 |
| EPCAM | 11529 | Breast Cancer | NA | NA | FACs | 0.32 | 0.211 | 28588211 |
| EPCAM | 11529 | Breast Cancer | NA | NA | FACs | 0.32 | 0.211 | 33799422 |
| EPCAM | 11529 | Breast Cancer | NA | NA | FACs | 0.32 | 0.211 | 34073849 |
| EPCAM | 11529 | Breast Cancer | NA | NA | FACs | 0.32 | 0.211 | 34572409 |
| GLI1 | 4317 | Breast Cancer | Ductal Carcinoma | NA | IHC staining | 0.32 | 0.0308 | 28965964 |
| HES1 | 5192 | Breast Cancer | NA | NA | IHC staining | 0.32 | 0.0095 | 33390847 |
| HSPA9 | 5244 | Breast Cancer | NA | NA | IHC staining | 0.32 | 0.0042 | 34249423 |
| UBQLN1 | 12508 | Breast Cancer | NA | NA | IHC staining | 0.32 | 0.0021 | 34528694 |
| VCP | 12666 | Breast Cancer | NA | NA | IHC staining | 0.32 | 0.0042 | 33731668 |
| AXIN2 | 904 | Breast Cancer | Ductal Carcinoma | Tamoxifen | SFA followed by qRT-PCR | 0.28 | 0.0064 | 31693936 |
| AXIN2 | 904 | Breast Cancer | Ductal Carcinoma | Tamoxifen+Fulvestrant | SFA followed by qRT-PCR | 0.28 | 0.0064 | 31693936 |
| B3GALT5 | 920 | Breast Cancer | NA | NA | qRT-PCR | 0.28 | 0.0011 | 33413566 |
| BOP1 | 15519 | Triple Negative Breast Cancer | NA | NA | qRT-PCR followed by SFA | 0.28 | 0.0021 | 33797754 |
| CCND1 | 1582 | Breast Cancer | Ductal Carcinoma | Tamoxifen | SFA followed by qRT-PCR | 0.28 | 0.0201 | 31693936 |
| CCND1 | 1582 | Breast Cancer | Ductal Carcinoma | Tamoxifen+Fulvestrant | SFA followed by qRT-PCR | 0.28 | 0.0201 | 31693936 |
| CTNNB1 | 2514 | Breast Cancer | Ductal Carcinoma | Tamoxifen | SFA followed by qRT-PCR | 0.28 | 0.0647 | 31693936 |
| CTNNB1 | 2514 | Breast Cancer | Ductal Carcinoma | Tamoxifen+Fulvestrant | SFA followed by qRT-PCR | 0.28 | 0.0647 | 31693936 |
| ESR1 | 3467 | Breast Cancer | NA | NA | SFA followed by qRT-PCR | 0.28 | 0.0042 | 31728117 |
| MIR205 | 31583 | Breast Cancer | Ductal Carcinoma | NA | qRT-PCR followed by Invasion assay and Tumorigenicity assay | 0.28 | 0.0032 | 30050081 |
| NOLC1 | 15608 | Breast Cancer | NA | NA | qPCR | 0.28 | 0.0042 | 34789263 |
| PiRNA-823 | NA | Breast Cancer | NA | NA | FACs for CSC marker followed by qRT-PCR and SFA | 0.28 | 0.0011 | 33791297 |
| SOD2 | 11180 | Breast Cancer | NA | NA | SFA followed by qRT-PCR | 0.28 | 0.0064 | 31728117 |
| TCF4 | 11634 | Breast Cancer | Ductal Carcinoma | Tamoxifen | SFA followed by qRT-PCR | 0.28 | 0.0032 | 31693936 |
| TCF4 | 11634 | Breast Cancer | Ductal Carcinoma | Tamoxifen+Fulvestrant | SFA followed by qRT-PCR | 0.28 | 0.0032 | 31693936 |
| TGFB1 | 11766 | Breast Cancer | NA | NA | SFA followed by qRT-PCR | 0.28 | 0.0138 | 31728117 |
| TMCC3 | 29199 | Breast Cancer | NA | NA | qRT-PCR | 0.28 | 0.0032 | 33742122 |
| TWIST1 | 12428 | Breast Cancer | NA | NA | FACs for CSC marker followed by qRT-PCR | 0.28 | 0.0191 | 33799422 |
| VEGF | 12680 | Breast Cancer | Ductal Carcinoma | Tamoxifen | SFA followed by qRT-PCR | 0.28 | 0.0042 | 31693936 |
| VEGF | 12680 | Breast Cancer | Ductal Carcinoma | Tamoxifen+Fulvestrant | SFA followed by qRT-PCR | 0.28 | 0.0042 | 31693936 |
| BRCA1 | 1100 | Breast Cancer | NA | NA | MACs followed by CFA | 0.2 | 0.0021 | 34377198 |
| CD24 | 1645 | Triple Negative Breast Cancer | NA | NA | SFA followed by FACs | 0.2 | 0.456 | 28883001 |
| CD44 | 1681 | Triple Negative Breast Cancer | NA | NA | SFA followed by FACs | 0.2 | 1 | 28883001 |
| CXCR2 | 6027 | Breast Cancer | NA | NA | FACs followed by SFA | 0.2 | 0.0011 | 34195201 |
| EPCAM | 11529 | Triple Negative Breast Cancer | NA | NA | SFA followed by FACs | 0.2 | 0.211 | 28883001 |
| ITGA6 | 6142 | Triple Negative Breast Cancer | NA | NA | SFA followed by FACs | 0.2 | 0.0265 | 28883001 |
| ITGB1 | 6153 | Breast Cancer | NA | NA | SFA followed by FACs | 0.2 | 0.018 | 35053617 |
| ITGB3 | 6156 | Breast Cancer | NA | NA | SFA followed by FACs | 0.2 | 0.0032 | 35053617 |
| LIN28A | 15986 | Breast Cancer | NA | NA | FACs | 0.2 | 0.0138 | 28588211 |
| PTPRC | 9666 | Breast Cancer | NA | NA | FACs | 0.2 | 0.0021 | 31555258 |
| PTPRC | 9666 | Breast Cancer | NA | NA | FACs | 0.2 | 0.0021 | 18685093 |
| PTPRC | 9666 | Breast Cancer | NA | NA | FACs | 0.2 | 0.0021 | 31555258 |
| PTPRC | 9666 | Breast Cancer | NA | NA | FACs followed by SFA | 0.2 | 0.0021 | 31555258 |